Systemic redox biomarkers in neurodegenerative diseases

Research output: Contribution to journalArticle

Abstract

Neurodegenerative diseases are characterized by a gradual and selective loss of neurons. ROS overload has been proved to occur early in this heterogeneous group of disorders, indicating oxidative stress as a primer factor underlying their pathogenesis. Given the importance of a better knowledge of the cause/effect of oxidative stress in the pathogenesis and evolution of neurodegeneration, recent efforts have been focused on the identification and determination of stable markers that may reflect systemic oxidative stress. This review provides an overview of these systemic redox biomarkers and their responsiveness to antioxidant therapies. Redox biomarkers can be classified as molecules that are modified by interactions with ROS in the microenvironment and antioxidant molecules that change in response to increased oxidative stress. DNA, lipids (including phospholipids), proteins and carbohydrates are examples of molecules that can be modified by excessive ROS in vivo. Some modifications have direct effects on molecule functions (e.g. to inhibit enzyme function), but others merely reflect the degree of oxidative stress in the local environment. Testing of redox biomarkers in neurodegenerative diseases has 3 important goals: 1) to confirm the presence or absence of systemic oxidative stress; 2) to identify possible underlying (and potentially reversible) causes of neurodegeneration; and 3) to estimate the severity of the disease and the risk of progression. Reflecting pathological processes occurring in the whole body, redox biomarkers may pinpoint novel therapeutic targets and lead to diagnose diseases before they are clinically evident.

Original languageEnglish
Pages (from-to)46-70
Number of pages25
JournalCurrent Drug Metabolism
Volume16
Issue number1
Publication statusPublished - Jul 1 2015

Fingerprint

Neurodegenerative diseases
Oxidative stress
Biomarkers
Neurodegenerative Diseases
Oxidation-Reduction
Oxidative Stress
Molecules
Antioxidants
Pathologic Processes
Neurons
Disease Progression
Phospholipids
Carbohydrates
Lipids
DNA
Testing
Enzymes
Therapeutics

Keywords

  • Antioxidants; antioxidant enzymes
  • Dietary antioxidants
  • Glutathione
  • Neurodegenerative diseases
  • Oxidative stress
  • Protein glutathionylation
  • Protein oxidation

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry

Cite this

Systemic redox biomarkers in neurodegenerative diseases. / Pastore, Anna; Petrillo, Sara; Piermarini, Emanuela; Piemonte, Fiorella.

In: Current Drug Metabolism, Vol. 16, No. 1, 01.07.2015, p. 46-70.

Research output: Contribution to journalArticle

@article{6817cdfa19354333b1075662fc75708f,
title = "Systemic redox biomarkers in neurodegenerative diseases",
abstract = "Neurodegenerative diseases are characterized by a gradual and selective loss of neurons. ROS overload has been proved to occur early in this heterogeneous group of disorders, indicating oxidative stress as a primer factor underlying their pathogenesis. Given the importance of a better knowledge of the cause/effect of oxidative stress in the pathogenesis and evolution of neurodegeneration, recent efforts have been focused on the identification and determination of stable markers that may reflect systemic oxidative stress. This review provides an overview of these systemic redox biomarkers and their responsiveness to antioxidant therapies. Redox biomarkers can be classified as molecules that are modified by interactions with ROS in the microenvironment and antioxidant molecules that change in response to increased oxidative stress. DNA, lipids (including phospholipids), proteins and carbohydrates are examples of molecules that can be modified by excessive ROS in vivo. Some modifications have direct effects on molecule functions (e.g. to inhibit enzyme function), but others merely reflect the degree of oxidative stress in the local environment. Testing of redox biomarkers in neurodegenerative diseases has 3 important goals: 1) to confirm the presence or absence of systemic oxidative stress; 2) to identify possible underlying (and potentially reversible) causes of neurodegeneration; and 3) to estimate the severity of the disease and the risk of progression. Reflecting pathological processes occurring in the whole body, redox biomarkers may pinpoint novel therapeutic targets and lead to diagnose diseases before they are clinically evident.",
keywords = "Antioxidants; antioxidant enzymes, Dietary antioxidants, Glutathione, Neurodegenerative diseases, Oxidative stress, Protein glutathionylation, Protein oxidation",
author = "Anna Pastore and Sara Petrillo and Emanuela Piermarini and Fiorella Piemonte",
year = "2015",
month = "7",
day = "1",
language = "English",
volume = "16",
pages = "46--70",
journal = "Current Drug Metabolism",
issn = "1389-2002",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Systemic redox biomarkers in neurodegenerative diseases

AU - Pastore, Anna

AU - Petrillo, Sara

AU - Piermarini, Emanuela

AU - Piemonte, Fiorella

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Neurodegenerative diseases are characterized by a gradual and selective loss of neurons. ROS overload has been proved to occur early in this heterogeneous group of disorders, indicating oxidative stress as a primer factor underlying their pathogenesis. Given the importance of a better knowledge of the cause/effect of oxidative stress in the pathogenesis and evolution of neurodegeneration, recent efforts have been focused on the identification and determination of stable markers that may reflect systemic oxidative stress. This review provides an overview of these systemic redox biomarkers and their responsiveness to antioxidant therapies. Redox biomarkers can be classified as molecules that are modified by interactions with ROS in the microenvironment and antioxidant molecules that change in response to increased oxidative stress. DNA, lipids (including phospholipids), proteins and carbohydrates are examples of molecules that can be modified by excessive ROS in vivo. Some modifications have direct effects on molecule functions (e.g. to inhibit enzyme function), but others merely reflect the degree of oxidative stress in the local environment. Testing of redox biomarkers in neurodegenerative diseases has 3 important goals: 1) to confirm the presence or absence of systemic oxidative stress; 2) to identify possible underlying (and potentially reversible) causes of neurodegeneration; and 3) to estimate the severity of the disease and the risk of progression. Reflecting pathological processes occurring in the whole body, redox biomarkers may pinpoint novel therapeutic targets and lead to diagnose diseases before they are clinically evident.

AB - Neurodegenerative diseases are characterized by a gradual and selective loss of neurons. ROS overload has been proved to occur early in this heterogeneous group of disorders, indicating oxidative stress as a primer factor underlying their pathogenesis. Given the importance of a better knowledge of the cause/effect of oxidative stress in the pathogenesis and evolution of neurodegeneration, recent efforts have been focused on the identification and determination of stable markers that may reflect systemic oxidative stress. This review provides an overview of these systemic redox biomarkers and their responsiveness to antioxidant therapies. Redox biomarkers can be classified as molecules that are modified by interactions with ROS in the microenvironment and antioxidant molecules that change in response to increased oxidative stress. DNA, lipids (including phospholipids), proteins and carbohydrates are examples of molecules that can be modified by excessive ROS in vivo. Some modifications have direct effects on molecule functions (e.g. to inhibit enzyme function), but others merely reflect the degree of oxidative stress in the local environment. Testing of redox biomarkers in neurodegenerative diseases has 3 important goals: 1) to confirm the presence or absence of systemic oxidative stress; 2) to identify possible underlying (and potentially reversible) causes of neurodegeneration; and 3) to estimate the severity of the disease and the risk of progression. Reflecting pathological processes occurring in the whole body, redox biomarkers may pinpoint novel therapeutic targets and lead to diagnose diseases before they are clinically evident.

KW - Antioxidants; antioxidant enzymes

KW - Dietary antioxidants

KW - Glutathione

KW - Neurodegenerative diseases

KW - Oxidative stress

KW - Protein glutathionylation

KW - Protein oxidation

UR - http://www.scopus.com/inward/record.url?scp=84937115674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937115674&partnerID=8YFLogxK

M3 - Article

C2 - 26152129

AN - SCOPUS:84937115674

VL - 16

SP - 46

EP - 70

JO - Current Drug Metabolism

JF - Current Drug Metabolism

SN - 1389-2002

IS - 1

ER -